http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 16:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Immunome+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26118573.html <p> BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> Each stock option has an exercise price per http://www.streetinsider.com/Press+Releases/Immunome+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26118573.html Thu, 05 Mar 2026 16:00:00 -0500 IMNM O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26118573.html <p> BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> Each stock option has an exercise price per http://www.streetinsider.com/Press+Releases/Immunome+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26118573.html Thu, 05 Mar 2026 16:00:00 -0500 IMNM O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26118573.html <p> BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> Each stock option has an exercise price per http://www.streetinsider.com/Business+Wire/Immunome+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26118573.html Thu, 05 Mar 2026 16:00:00 -0500 IMNM O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26118573.html <p> BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> Each stock option has an exercise price per http://www.streetinsider.com/Business+Wire/Immunome+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26118573.html Thu, 05 Mar 2026 16:00:00 -0500 IMNM O.48629524 http://www.streetinsider.com/Analyst+PT+Change/Immunome+Inc.+%28IMNM%29+PT+Lowered+to+%2430+at+Lake+Street+/26115903.html <p>Lake Street analyst Chad Messer lowered the price target on Immunome Inc. (NASDAQ: IMNM) to $30.00 (from $32.00) while maintaining a Buy rating.</p> http://www.streetinsider.com/Analyst+PT+Change/Immunome+Inc.+%28IMNM%29+PT+Lowered+to+%2430+at+Lake+Street+/26115903.html Thu, 05 Mar 2026 08:53:18 -0500 IMNM http://www.streetinsider.com/Analyst+PT+Change/Immunome+Inc.+%28IMNM%29+PT+Raised+to+%2436+at+Craig-Hallum/26108168.html Craig-Hallum analyst Adam Vogel raised the price target on Immunome Inc. (NASDAQ: IMNM) to $36.00 (from $33.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Immunome+Inc.+%28IMNM%29+PT+Raised+to+%2436+at+Craig-Hallum/26108168.html Wed, 04 Mar 2026 09:05:28 -0500 IMNM http://www.streetinsider.com/Analyst+PT+Change/Immunome+Inc.+%28IMNM%29+PT+Lowered+to+%2430+at+Stephens/26107077.html Stephens analyst Sudan Loganthan lowered the price target on Immunome Inc. (NASDAQ: IMNM) to $30.00 (from $33.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Immunome+Inc.+%28IMNM%29+PT+Lowered+to+%2430+at+Stephens/26107077.html Wed, 04 Mar 2026 07:16:14 -0500 IMNM http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Immunome+Inc.++++++++++++++++++++++++/26101943.html si-local-file:///var/storage/secattach/20260303/26101943.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Immunome+Inc.++++++++++++++++++++++++/26101943.html Tue, 03 Mar 2026 16:27:00 -0500 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Immunome+Inc.++++++++++++++++++++++++/26101943.html si-local-file:///var/storage/secattach/20260303/26101943.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Immunome+Inc.++++++++++++++++++++++++/26101943.html Tue, 03 Mar 2026 16:27:00 -0500 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Immunome+Inc.+++++++++++++For%3A+Dec+31/26101405.html si-local-file:///var/storage/secattach/20260303/26101405.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Immunome+Inc.+++++++++++++For%3A+Dec+31/26101405.html Tue, 03 Mar 2026 16:11:00 -0500 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Immunome+Inc.+++++++++++++For%3A+Dec+31/26101405.html si-local-file:///var/storage/secattach/20260303/26101405.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Immunome+Inc.+++++++++++++For%3A+Dec+31/26101405.html Tue, 03 Mar 2026 16:11:00 -0500 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunome+Inc.+++++++++++++For%3A+Mar+03/26101254.html si-local-file:///var/storage/secattach/20260303/26101254.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunome+Inc.+++++++++++++For%3A+Mar+03/26101254.html Tue, 03 Mar 2026 16:07:00 -0500 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunome+Inc.+++++++++++++For%3A+Mar+03/26101254.html si-local-file:///var/storage/secattach/20260303/26101254.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunome+Inc.+++++++++++++For%3A+Mar+03/26101254.html Tue, 03 Mar 2026 16:07:00 -0500 IMNM O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Press+Releases/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html <ul class="bwlistdisc"> <li> New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 </li> <li> IM-1021 Phase 1 ongoing with initial data expected in 2026 </li> <li> Three IND submissions for solid tumor-targeted ADC programs planned in 2026 </li> <li> Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54436938&amp;newsitemid=20260303337450&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=090a2b2f00ffef4cf9a57b9952791b4b" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. </p><p> “Immunome made substantial progress in 2025. The http://www.streetinsider.com/Business+Wire/Immunome+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26101053.html Tue, 03 Mar 2026 16:02:00 -0500 A.06822034 A.25552276 IMNM O.19942534 O.20026344 O.48629524